Given the implication of Gal-3 and Gal-9 in metabolic pathways that regulate tumor progression, we designed and synthesized a new molecule, SeDG-Bn, able to bind Gal-3CRD and Gal-9NCRD and affect tumor cell mobility, invasion, and angiogenesis. This evidence concerns the gene GAL and neoplasm.